Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...

SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations amenable to exon 51 skipping. With this ...

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated ...

The company noted at the time that cases of hypomagnesemia—or abnormally low magnesium—had previously been identified and ...

Older hospitalized adults with both magnesium and calcium deficiencies exhibit significantly lower cognitive function, highlighting the need for nutrient monitoring in aging populations.

Magnesium, the fourth most prevalent mineral in the human body, plays a crucial role in significant metabolic and biochemical processes within cells A recent study hypothesizes that magnesium ...